J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Overweight
Obesity
Спонсор: Eli Lilly & Co.
Налично на:
БГ
Обобщение
Trial status: Authorised
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 238 participants
БГ
EN